Expert Interview
A Closer Look at Avalyn Pharma’s Inhaled Pulmonary Fibrosis Clinical Pipeline with AP01 and AP02 Ahead of the Company IPO
Ticker(s): AVALYN PHARMA, RHHBY, Boehringer IngelheimInstitution: UCLA School of Medicine
- Professor of Medicine and Pulmonology at UCLA
- Medical Director of the Lung Institute at Cedars Sinai who has experience managing patients with the Zephyr and Spiration valve. Sees 200 patients with COPD and emphysema
- Research interest in pulmonary exercise physiology, hyperinflation, emphysema and non-invasive lung volume reduction in emphysema.
On a scale of 1 to 10, how excited are you for either APO1 and APO2?
Added By: max_adminIs there a need to develop inhaled versions of Esbriet and Ofev?
Added By: ben_adminWhat are the limitations of oral pulmonary fibrosis drugs?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
